DDInter704 DDInter1615
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its ligand Substance P, which is released in the gut following chemotherapy administration. Neurokinin-1 is also known as Tachykinin Receptor 1 (TACR1), Neurokinin 1 Receptor (NK1R), and Substance P Receptor (SPR). By blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system, rolapitant prevents late-phase CINV. Unlike other available NK-1 receptor antagonists, rolapitant is not an inhibitor of Cytochrome P450 enzyme CYP3A4 and has a long elimination half-life, allowing a single dose to prevent both acute and late-phase CINV during the first 120 hours post-chemotherapy.
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rolapitant
Everolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Tolterodine
Tolterodine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Rolapitant
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolterodine
Tolterodine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Rolapitant
Everolimus {u} (Compound) causes {v} (Side Effect) Dry mouth
Dry mouth {u} (Side Effect) is caused by {v} (Compound) Tolterodine
Tolterodine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Rolapitant
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Larotrectinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rolapitant
Everolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Dextromethorphan
Dextromethorphan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rolapitant
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Flibanserin
Flibanserin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rolapitant
Everolimus {u} (Compound) causes {v} (Side Effect) Dry mouth
Dry mouth {u} (Side Effect) is caused by {v} (Compound) Iloperidone
Iloperidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rolapitant
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinblastine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rolapitant
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may lead to a major life threatening interaction when taken with {v} Teriflunomide
Teriflunomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rolapitant
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Everolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Tolterodine (Compound) and Tolterodine may cause a minor interaction that can limit clinical effects when taken with Rolapitant
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine may cause a minor interaction that can limit clinical effects when taken with Rolapitant
Everolimus (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Tolterodine (Compound) and Tolterodine may cause a minor interaction that can limit clinical effects when taken with Rolapitant
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Everolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dextromethorphan (Compound) and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin and Flibanserin may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Everolimus (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Iloperidone (Compound) and Iloperidone may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant